ReviewSeminars in dialysis
Thrombosis in the uremic milieu--emerging role of "thrombolome".
Review in Seminars in dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2.Blood vessels, thrombosis & hemostasis · 2026Article
- The Role of Downstream Kynurenine Pathway Metabolites in the Modulation of Cardiovascular Disease Development in Chronic Kidney Disease.International journal of tryptophan research : IJTR · 2026Review
- Serum Uric Acid Level as an Estimated Parameter That Predicts All-Cause Mortality in Patients with Hemodialysis.Journal of personalized medicine · 2025Article
- Clinical management of peripheral arterial disease in chronic kidney disease-a comprehensive review from the European Renal Association CKD-MBD Working Group.Clinical kidney journal · 2025Review
- Revisiting Virchow's triad: exploring the cellular and molecular alterations in cerebral venous congestion.Cell & bioscience · 2024Article
- The in-vitro influence of urea concentration on thromboelastrography in patients with and without end stage renal disease.American journal of surgery · 2023Article
- Asperulosidic Acid Ameliorates Renal Interstitial Fibrosis via Removing Indoxyl Sulfate by Up-Regulating Organic Anion Transporters in a Unilateral Ureteral Obstruction Mice Model.Molecules (Basel, Switzerland) · 2023Article
- Tissue Factor, Thrombosis, and Chronic Kidney Disease.Biomedicines · 2022Review
- COVID-19 and Peripheral Artery Thrombosis: A Mini Review.Current problems in cardiology · 2022Review
- Venous Thromboembolism in Kidney Diseases and Genetic Predisposition.Kidney diseases (Basel, Switzerland) · 2022Review
- Uremic serum induces prothrombotic changes in venous endothelial cells and inflammatory changes in aortic endothelial cells.Renal failure · 2021Article
- Consequences of oral antithrombotic use in patients with chronic kidney disease.Clinical and translational science · 2021Article
- Determinants of Hemodialysis Performance: Modeling Fluid and Solute Transport in Hollow-Fiber Dialyzers.Regenerative engineering and translational medicine · 2021Article
- Review
- The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.American journal of nephrology · 2021Review
- Review
- Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation.Journal of clinical medicine · 2020Article
- Assessment of Thrombotic and Bleeding Tendency in Two Mouse Models of Chronic Kidney Disease: Adenine-Diet and 5/6th Nephrectomy.TH open : companion journal to thrombosis and haemostasis · 2020Article
- Article
- Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.Journal of the American Society of Nephrology : JASN · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic kidney disease (CKD) is characterized by retention of a number of toxins, which unleash cellular damage. CKD environment with these toxins and a host of metabolic abnormalities (collectively termed as uremic milieu) is highly thrombogenic. CKD represents a strong and independent risk factor for both spontaneous venous and arterial (postvascular injury) thrombosis. Emerging evidence points to a previously unrecognized role of some of the prothrombotic uremic toxins. Here, we provide an overview of thrombosis in CKD and an update on indolic uremic toxins, which robustly increase tissue factor, a potent procoagulant, in several vascular cell types enhancing thrombosis. This panel of uremic toxins, which we term "thrombolome" (thrombosis and metabolome), represents a novel risk factor for thrombosis and can be further explored as biomarker for postvascular interventional thrombosis in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.